Global Melanoma Drugs Market will reach USD 4.71 Billion by

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
244
Global Melanoma Drugs Market will reach USD 4.71 Billion by 2022: Zion Market Research

Sarasota, FL, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Melanoma Drugs Market by Therapy (Chemotherapy, Immunotherapy and Targeted Therapy) and Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022” . According to the report, global  melanoma drugs market  was valued at approximately USD 2.04 billion in 2016 and is expected to generate revenue of around USD 4.71 billion by end of 2022, growing at a CAGR of around 15.0% between 2016 and 2022. 

Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the skin and is most common because most pigment cells are found in the skin. Mucosal melanoma is melanoma of mucous membrane of the body, including the mouth, the nasal passages, the throat, the vagina or the anus. The rare ocular melanoma or uveal melanoma occurs in the eye.

Browse through 27 Market Tables and 14 Figures spread through 110 Pages and in-depth TOC on “Global Melanoma Drugs Market: By Type, Therapy, Size, Share, Trends, Segments, Analysis and Forecast 2016 – 2022”.

Request Free Sample copy of Melanoma Drugs Market Report @ https://www.zionmarketresearch.com/sample/mel...ugs-market

Global melanoma drugs market is primarily driven by growing incidences of target disease across the globe. Other major driving factors are the development of novel agents and combination therapy with lesser side effects and better survival. However, the high price of combination therapies and clinical trials coupled along with possible adverse events or side effects are the major restraints that may limit the growth of the market. Nonetheless increasing focus on personalized medicine coupled along with huge investment in anti-melanoma drugs research across the globe are likely to disclose the new avenues for melanoma drugs market in the near future.

The melanoma drugs market is segmented on the basis of the different therapeutic segment including chemotherapy, immunotherapy and targeted therapy. FDA approved immunotherapy agents such as pembrolizumab and nivolumab, which are under pipeline studies of many key players. Thus immunotherapy segment is expected to grow at the fastest rate during the forecast period.

Browse the full " Melanoma Drugs Market by Therapy (Chemotherapy, Immunotherapy and Targeted Therapy) and Region: Global Industry Perspective, Comprehensive   Analysis, and Forecast, 2016 - 2022 " report at  https://www.zionmarketresearch.com/report/mel...ugs-market

North America represents developed regional markets for melanoma drugs and is expected to see the rapid growth in the years to come. The U.S. is by far the leading melanoma drugs market by country in North America. The U.S. market is expected to grow at the highest CAGR during the forecast period. This growth is mainly due to the high prevalence of melanoma coupled with well-developed healthcare infrastructure and the increase in research and development on melanoma drugs. Moreover, the disposable income and reimbursement of life threatening diseases are very high in this region which promotes the growth of melanoma drugs market. 

Europe was the second largest regional market and is expected to show significant growth in the years to come. This growth is mainly due to increase in a number of patients diagnosed with melanoma and entry of novel therapies in the market.

Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/me...ugs-market

Asia-Pacific is expected to witness slow growth in the near future. This low growth is mainly attributed to the lower incidence rate of skin cancer in the Asian population. Thus Asia Pacific will slow-growing markets in melanoma drugs market.

In Middle East & Africa; African region is projected to register low growth rate due to lack of awareness and the high cost of melanoma drugs. Latin America is another important regional market and is expected to experience moderate growth over the forecast period. Thus, all the aforementioned parameters are expected to propel the market growth in this region.

Request customized copy of report @ https://www.zionmarketresearch.com/custom/889

Some of the key players in Melanoma drugs market include Amgen, Bristol-Myers Squibb, Hoffmann-La Roche Ltd, Genentech Inc., Janssen Biotech, Inc., Novartis International AG., Pfizer, Sanofi, Takeda Pharmaceutical Company Limited and Teva Pharmaceuticals among others.

For more inquiry contact our sales team @ sales@zionmarketresearch.com

This report segments the global melanoma drugs market as follows:

Global Melanoma Drugs Market: Therapy Segment Analysis

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

Global Melanoma Drugs Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Related Reports:

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research

Follow Us Twitter: https://twitter.com/zion_research

Contact Us: Joel John 4283, Express Lane, Suite 634-143, Sarasota, Florida 34249, United States Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651 Email: sales@zionmarketresearch.com Website: https://www.zionmarketresearch.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WellLink Advisory Board Eyes Future of Healthcare Innovation

Updated Category News Views 3

Strategic Collaboration for Healthcare Evolution Ready to shake things up in healthcare, WellLink is setting the stage with its brand new Advisory Board. This move isn’t just about having fancy titles sitting around a conference table — it's about grabbing onto the future with both hands and figuring out just what the heck the healthcare industry needs next....

Continue Reading
G-STAR & Wu-Tang Clan Unleash Denim Fusion

Updated Category News Views 5

Denim and Old-School Beats: A Fresh Partnership Just when you think fashion collaborations have run their course, along comes something worth the buzz. This fall, G-STAR, the edgy Dutch denim frontrunner, and the legendary hip-hop collective of Wu-Tang Clan are shaking up the apparel scene, blending raw denim with raw rap. It's a multi-year collaboration that doesn't slap...

Continue Reading
TWP & Commbi Unveil Exclusive Pony Clog Collaboration

Updated Category News Views 5

A Fusion of Fashion and Functionality Walk down the streets of New York or hustle your way through an airport without worrying about your footwear weighing you down. That's the promise coming from the fresh alliance between TWP and Commbi with their new Pony Clog Collaboration. A blend of high fashion and everyday utility, these clogs aren't just keeping up with the...

Continue Reading
Perk's U.S. Expansion: A Bold Move in Spend Control

Updated Category News Views 5

Perk Aims for U.S. Growth: Will It Pay Off? Amidst the cacophony of market chatter, Perk's announcement to bring its spend platform stateside is echoing louder than usual. This move is not just another step in its expansion but rather a leap considering the competition and market needs. In Europe, where they've already captured a chunk of the market with their Travel and...

Continue Reading
BMAP Expands: Bridging Borders in Legal Advocacy

Updated Category News Views 4

Breaking Down BMAP's Unique Approach Just when you thought you've seen it all, along comes LMU Loyola Law School swinging the doors wide open with their Binational Migrant Advocacy Project, or as we’re affectionately calling it, BMAP. It's a mouthful, sure, but ain't it something? This project isn't just another feather in academia's cap—it's a relentless counterpunch...

Continue Reading
NY Sheriffs' Court Battle: Immigration Policies Under Fire

Updated Category News Views 5

Sheriffs Clash with State Over Immigration Policies In a tense showdown reminiscent of an old-time standoff, 15 New York county sheriffs have drawn their battle lines against the state’s capricious maneuvers by pushing a federal court to hit the brakes on Albany’s newly minted immigration rule. The so-called “Local Cops, Local Crimes Act” is catching serious heat,...

Continue Reading
Lumicell Expands LumiSystem in Breast Cancer Surgery

Updated Category News Views 6

Innovation in Breast Cancer Surgery: A Real-World Game Changer? You’ve got your flashlight guiding a scared child through the dark, and in the healthcare world, Lumicell is promising to do just that for surgeons navigating the tricky maze of breast cancer surgery. Their LumiSystem is making waves in breast-conserving surgery—new kid on the block with a real chance at...

Continue Reading
Feeding Families Foundation Gains $121,500 for NYC Push

Updated Category News Views 5

Holy smokes, here comes some good news in the nonprofit corners! Feeding Families Foundation just got a hefty $121,500 boost from the Association of Contracting Plumbers of the City of New York Inc. This ain't just some pocket change; it's a full-fledged lifeline that helps them keep on delivering meals to parents who are practically living at their kid’s hospital...

Continue Reading
Orthopedic Expert Highlighting Midwest Pain Access Gaps

Updated Category News Views 5

Over in the vast sprawl of rolling plains and prairie winds, folks in the Upper Midwest are grappling with an ironic reality. As technological advancements blaze trails, people suffering from vertebrogenic pain are finding themselves up against a wall of limited access to specialized care. We’ve got Dr. James T. Brunz, the man of the hour, one of only about 15 Intracept...

Continue Reading
Citrine Finalizes Sale of Illinois Senior Living Asset

Updated Category News Views 6

Citrine's Strategic Exit from River Glen Every now and then, you see a company pull off something that makes you nod and say, "That was smart." Citrine Investment Group's sale of River Glen of St. Charles fits that bill. For those keeping tabs, this wasn't some quick flip—Citrine worked on the rock for a good while before cashing in. They secured River Glen back in...

Continue Reading

Top 5 Most Recently Viewed Articles

Mullen Automotive Faces Securities Fraud Lawsuit Opportunities

Updated Category News Views 276

Mullen Automotive Securities Fraud Lawsuit Overview Mullen Automotive, Inc. (NASDAQ: MULN) is currently facing significant legal scrutiny as investors step forward to address alleged discrepancies in information provided by the company. This situation presents both challenges and opportunities for investors who purchased securities during a specified period. What...

Continue Reading
Microsoft and OpenAI: Navigating a Complex Financial Partnership

Updated Category News Views 256

Understanding the Microsoft and OpenAI Valuation Dynamics OpenAI and Microsoft Corp MSFT are currently engaged in critical negotiations to convert Microsoft's noteworthy $14 billion investment into shares within OpenAI. This transition illustrates the evolving landscape of investment in artificial intelligence. The Impact of OpenAI's Valuation on Negotiations Recen

Continue Reading
Legal Battle Between CrowdStrike and Delta Over Flight Issues

Updated Category News Views 264

CrowdStrike and Delta Engage in Legal Dispute In a significant legal battle, CrowdStrike (NASDAQ: CRWD), a well-known cybersecurity firm, has initiated a lawsuit against Delta Air Lines (NYSE: DAL). This action comes in response to a major incident stemming from a faulty software update that caused extensive flight disruptions globally. The lawsuit was filed in U.S....

Continue Reading
Apranga Group Reports Impressive Growth in Retail Turnover

Updated Category News Views 54

Apranga Group rolled out some impressive numbers back in September 2024, reporting a retail turnover of EUR 28.5 million. That marked a solid increase of 6.5% compared to the same month last year, showing the group's hustle to bolster its market presence. But here’s where things get spicy: while Lithuania showed decent growth at 6.3%, Latvia shot up with a staggering...

Continue Reading
ePayPolicy Celebrates Continued Growth with Inc. 5000 Recognition

Updated Category News Views 164

ePayPolicy Achieves Recognition on Inc. 5000 List ePayPolicy has once again made a mark by securing the No. 1759 spot on this year's Inc. 5000 list, an esteemed recognition celebrating the fastest-growing private companies in the United States. This achievement highlights the company's consistent dedication and the expanding reach of its insurance payments platform....

Continue Reading